Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry represents a collection of six distinct pharmaceutical agents—tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, and toremifene—all primarily utilized in the endocrine therapy of hormone receptor-positive breast cancer. These drugs employ varied mechanisms to disrupt estrogen signaling, a key driver of growth in many breast cancers. Tamoxifen and toremifene are Selective Estrogen Receptor Modulators (SERMs), acting as estrogen antagonists in breast tissue while exhibiting partial agonist effects in other tissues like bone and uterus. Anastrozole, exemestane, and letrozole are Aromatase Inhibitors (AIs). Anastrozole and letrozole are non-steroidal and reversibly inhibit the aromatase enzyme, which is responsible for converting androgens into estrogen in postmenopausal women. Exemestane is a steroidal, irreversible aromatase inactivator. Fulvestrant is a Selective Estrogen Receptor Degrader (SERD) and a pure estrogen receptor antagonist, causing the degradation and downregulation of the estrogen receptor protein, thereby completely blocking its activity without any agonist effects. These agents are crucial in both adjuvant and metastatic settings for breast cancer treatment, often used sequentially or in combination with other therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tamoxifen + anastrozole + exemestane + letrozole + fulvestrant + toremifene.